MDFI is a novel biomarker for poor prognosis in LUAD

Abstract excerpt

Background Approximately 80% of lung cancers are non-small cell lung cancers (NSCLC). Lung adenocarcinoma (LUAD) is the main subtype of NSCLC. The incidence and mortality of lung cancer are also increasing yearly. Myogenic differentiation family inhibitor (MDFI) as a transcription factor, its role in lung cancer has not yet been clarified. Methods LUAD data were downloaded from The Cancer Genome Atlas (TCGA)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related molecular mechanisms research
• Share to Ferroptosis and cancer prognosis
• Share to RNA modifications and cancer